Dyer et al. (this issue) assess the risk of new basal cell carcinoma (BCC) in the Veterans Affairs topical tretinoin chemoprevention trial, which included individuals with a history of at least two prior keratinocyte carcinomas. In addition to known risk factors for a future BCC, such as number of prior BCCs, a history of eczema and lower education levels were also associated with greater risk.
Introduction
Among individuals with a primary basal cell carcinoma (BCC), 44% will develop a subsequent BCC within 3 years, a 10-fold higher incidence than the general population (Marcil and Stern, 2000) . Dyer et al. (2012, this issue) again illustrate the high rate of BCC development in individuals at high risk for skin cancer, particularly those with a prior history of keratinocyte carcinoma (KC; e.g., BCC or squamous cell carcinoma (SCC)). Because BCCs are so common, their treatment is a considerable health-care burden, especially in Medicare and Veterans Affairs (VA) populations. Therefore, identifying modifiable risk factors for new BCC in high-risk, nonimmunosuppressed patients is a priority. Dyer et al. (2012) present data on risk factors for BCC on the face or ears in 1131 VA patients with at least two prior KCs, who were enrolled in the VA topical tretinoin chemoprevention (VATTC) trial and followed up for a median of 3.6 years.
Previously identified risk factors for future BCC
Several studies have evaluated risk factors for the development of subsequent BCCs after primary BCC or SCC, excluding BCC recurrence (Marcil and Stern, 2000; Karagas et al., 1992) . The only consistent risk factor for subsequent BCC in a meta-analysis was the number of previous skin cancers, whereas conflicting results were found for age and sex (Marcil and Stern, 2000) . Other studies have found an association with skin type, solar skin damage, and recreational sun exposure (Karagas et al., 1992) . As with the aforementioned studies, the number of prior BCCs was the most significant risk factor for the development of new BCCs on the face or ears in VATTC participants (hazard rate ratio (HRR) 4.01; 95% confidence interval (CI): 3.02-5.31), but several other unique risk factors, such as history of eczema and lower education level, were also identified in this largely older Caucasian male VA population.
History of eczema
Dyer et al. (2012) report that the 52 VATTC participants with a history of eczema had a 54% higher risk of developing new BCC on the face and ears (multivariate HRR 1.54; 95% CI 1.03-2.32). History of eczema was based on subjects' self-report of ever being told by a doctor that they had eczema, without further information on timing, duration, or severity of eczema. Several studies have evaluated the association between atopic dermatitis or eczema and non-melanoma skin cancer (NMSC), with inconsistent results (Arana et al., 2010; Tennis et al., 2011; Jensen et al., 2012) , but the data presented by Dyer et al. (2012) are the first to consider the history of eczema in a high-risk population.
A review by Tennis et al. (2011) highlighted the inconsistent findings on eczema and NMSC, noting that two clinic-based, case-control studies reported a protective relationship between eczema and NMSC, whereas two hospital-based cohort studies reported a greater risk of NMSC among patients discharged with an eczema diagnosis. Since this review, two additional cohort studies have found a 1.4-fold higher risk of NMSC in individuals with a diagnosis of eczema. The first, a retrospective cohort study in The Health Improvement Network, representative of the general UK population, found that individuals with eczema had a 46% greater risk of NMSC (e.g., BCC and SCC combined), but the analysis only adjusted for sex and age, as skin cancer risk factors and history of eczema treatments were unavailable (incidence rate ratio 1.46; 95% CI 1.27-1.69; Arana et al., 2010) . Similarly, in a Danish hospital-based cohort study, patients with a diagnosis of eczema and asthma had a 41% higher risk of BCC (standardized incidence ratio (SIR) 1.41; 95% CI 1.07-1.83), but diagnosis of eczema alone was not associated significantly with BCC (SIR 1.29; 95% CI 0.92-1.77; Jensen et al., 2012) . Comparing the studies of eczema and NMSC is challenging, as determination of eczema status varied greatly in each (from mailed-surveys to discharge diagnoses codes), and adjustment for skin cancer risk factors was limited. In addition, few of these studies assessed eczema severity, duration, and timing in relation to the development of NMSC.
It is uncertain whether the association of eczema with BCC is causal. Eczema could increase BCC risk secondary to chronic inflammation or to the possible use of carcinogenic or immunosuppressive treatments for patients with severe disease (Arana et al., 2010; Jensen et al., mutagenesis and thus increases cancer risk (Arana et al., 2010) . Classically, eczema involves the flexural surfaces of extremities, so the greater risk of BCC in VATTC participants was in areas generally unaffected by adult forms of atopic eczema (e.g., face or ears), thus seemingly reducing the likelihood that chronic inflammation may have predisposed these patients to skin cancer.
Others cite the carcinogenic potential of certain eczema treatments, such as topical calcineurin inhibitors. These agents have carried a ''black box'' warning since 2006, owing to concern that they may be associated with a higher risk of skin cancer and lymphoma (both cutaneous and non-cutaneous), based on results from animal models and case reports (Tennis et al., 2011). However, epidemiological studies have not supported a link between topical calcineurin inhibitors and skin cancer (Tennis et al., 2011) . Notably, none of the VATTC participants with eczema had used topical calcineurin inhibitors. Other treatments for severe eczema that have been cited for their immunosuppressive or carcinogenic potential include oral calcineurin inhibitors, azathioprine, oral glucocorticoids, and UV phototherapy (Jensen et al., 2012), but these were not evaluated in the VATTC participants.
Increased surveillance may explain the higher incidence of BCC in some patients with eczema, as they may be more likely to have skin examinations compared with the general population. However, this does not account for the higher risk of new BCC in VATTC participants with a history of eczema, as all individuals in the trial underwent regular skin examinations. Thus, the results by Dyer et al. (2012) may be explained either by a chance finding in a small population (n ¼ 52) or because either eczema or its treatment may lead to a higher risk of BCC in areas otherwise unaffected by eczema (e.g., the face or ears).
Education
In VATTC participants, higher education (e.g., some college versus no college) was protective against new BCCs. Commonly, in low-risk, general populations, higher education is associated with higher risk of BCC, probably secondary to the patterns of sun exposure seen in high socioeconomic groups (e.g., high, intermittent sun exposure during outdoor activities or on vacations; Steding-Jessen et al., 2010). Americans from low socioeconomic groups, either based on education or income, are less likely to have skin examinations (Saraiya et al., 2004) and to use sunscreens (Buller et al., 2011) . In this high-risk population, patients with higher education may have practiced more sun-protective behaviors such as sun avoidance and sunscreen use.
Sun exposure and sunscreen use
Dyer et al. (2012) also report that occupational sun exposure before the age of 30 years was associated with higher risk of new BCC of the face or ears, consistent with a meta-analysis that found a 40% higher risk of BCC with occupational UV exposure (Bauer et al., 2011) . Other sun exposure variables were not associated with BCC risk, including occupational sun exposure after the age of 30 years, recreational time spent outside, sunburns, and latitude of residence. Dyer et al. (2012) also report that SPF15 þ use in the last week was associated with a higher risk of new BCC (HRR 1.25, 95% CI 1.01-1.54), whereas there was no association with SPF15 þ use in the last 6 months or with any sunscreen use (regardless of SPF; Dyer et al., 2012). Sunscreen use and higher SPF have been associated with greater duration of sun exposure and higher numbers of sunburns (Autier et al., 2007) . Thus, the individuals using SPF15 þ in the last week may have been at higher risk for BCC, but the findings by Dyer et al. (2012) on sunscreen use also highlight that sun-protective behaviors in individuals with a history of skin cancer may be insufficient to prevent new BCCs.
Conclusion
The report by Dyer et al. (2012) not only confirms that prior BCCs are an important predictor of future BCCs, but also highlights the need for further research on risk factors for new BCCs in high-risk, non-immunosuppressed populations. Prior studies in the general population have suggested that eczema is associated with greater risk of NMSC. Similarly, Dyer et al. (2012) found that history of eczema (n ¼ 52), in the absence of topical calcineurin inhibitor use, was a risk factor for new BCCs of the face and ears in high-risk individuals. Interestingly, the new BCCs were in areas not classically affected by eczema. It is unclear whether the association between eczema and NMSC is secondary to the chronic inflammatory disease state or to the treatments for severe eczema that may be carcinogenic or immunosuppressive. Notably, greater skin surveillance in patients with eczema is unlikely to explain the higher risk of BCC in the VATTC participants, as skin examinations were performed routinely as part of the trial. This report adds further credence to epidemiological studies that have found no association between topical calcineurin inhibitors and NMSC by highlighting the issue of confounding by indication, whereas topical calcineurin inhibitors may be associated with NMSC if used to treat eczema, which is independently associated with NMSC. Relevant areas for future research include analysis of eczema severity, duration, timing, and treatment in relation to the development of NMSC, as well as further studies of a potential biological mechanism.
